Envision Healthcare (EVHC) Tops Q2 EPS by 3c

Envision Healthcare (NYSE: EVHC) reported Q2 EPS of $0.28, $0.03 better than the analyst estimate of $0.25. Revenue for the quarter came in at $1.08 billion versus the consensus estimate of $1.04 billion.

William A. Sanger, president and chief executive officer, said, “Our integrated service offerings across our business segments continue to differentiate us in the market as evidenced by our strong revenue and EBITDA growth. Approximately 60% of our revenue growth was driven by net new contract wins, 25% from same store and 15% from acquisitions. EmCare’s net new contract wins continued at a record pace and contributed 15.4% to its overall revenue growth of 21.2%. AMR delivered its strongest performance in many years, with 16.7% revenue and 33.1% EBITDA growth.

“With respect to healthcare reform, we have seen a meaningful shift from self-pay into both Medicaid and healthcare exchange programs. We anticipate this positive trend to continue, resulting in additional volume and improved rates.

“Given the strength of our business, along with the positive benefits of healthcare reform, we are increasing our guidance for the full year.”

For earnings history and earnings-related data on Envision Healthcare (EVHC) click here.

You May Also Be Interested In

• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Grandstand Limited (GRSD) Tops Q2 EPS by 5c; Offers Guidance
• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance